Russia Says Preliminary Studies Show Sputnik and AstraZeneca Vaccine Combination Safe

Previous results of the Russian anti-ovid vaccine combination survey Sputnik V and the British AstraZeneca taking place in Azerbaijan show its high level of security and the absence of serious adverse reactions, the Russian Direct Investment Fund (FIDR) reported on Friday.

“Interim analysis of the data shows high safety indicators of the combined use of drugs: no serious adverse phenomenon or case of coronavirus infection is observed after vaccination, ”said FIDR, which promotes and markets the Russian vaccine, in a press release.

The vaccine combination was applied to a small group of 50 volunteers in Azerbaijan.

It is expected that phases I and II clinical trials of this “cocktail” last up to March 2022.

According to the Gamaleya Center, developer of Sputnik V, in a vaccine that uses different human adenoviruses as vectors in its two components, the first of them can be used as a single-dose preparation, which has received the name of Sputnik light.

Russian scientists argue that the use of two different vectors provides a longer immunity than two-dose vaccines using the same vector.

Currently, clinical studies of the combination are also underway in the United Arab Emirates and Argentina.

According to FIDR, the first results of tests carried out in Azerbaijan will be published next August.

Kirill Dmitriev, Managing Director (CEO) of Russia’s Direct Investment Fund (RDIF) said: “As new strains of coronavirus emerge, partnerships between vaccine makers and combinations different drugs play a key role to successfully fight the pandemic ”.

While Irina Panarina, Managing Director of AstraZeneca, Russia and Eurasia, declared: “The heterogeneous primary booster is one of the vaccination schedules to be studied. the most promising. It becomes particularly relevant now, while the issue of preventing the spread of new strains of coronavirus infection is vital and the population’s need for revaccination is also growing ”.

For his part, Vasily Ignatiev, CEO of the “R-Pharm” group, commented: “The first results obtained during the spread of the Delta strain of the coronavirus are very important to assess the safety and early efficacy of the vaccine combination. We will continue to research and analyze the data for publication in an international journal. “

Argentina adds Modern

the Moderna dose will be included in the study of combined schedules conducted by the Ministry of Health to authorize heterologous vaccination schedules against the coronavirus, i.e. the possibility of using vaccines from different laboratories in the same vaccination.

“We have defined the incorporation of the Moderna vaccine in studies that seek to determine the safety and immunity in the vaccine combination“Said Minister Carla Vizzotti and added that” progressing in the production of scientific evidence in this regard is very important in order to have a wider range of possibilities to carry out complete (vaccination) schedules as soon as possible ” .

The study in question is “collaborative and federal”, and is coordinated with the participating jurisdictions (Buenos Aires, Córdoba, La Rioja, Mendoza and San Luis) and researchers from the National Council for Scientific and Technical Research (CONICET).

The scientific work aims “to have national evidence for decision-making based on the analysis of the immunogenicity and safety of using different doses in the same regimen,” as the official statement said.

So far, dose combinations of AstraZeneca, China Sinopharm and russian Sputnik V, the latter is the one with the longest delay for the second applications.

The study involves volunteers over 18 vaccinated with a dose of one of these three vaccines “up to 60 days before enrollment”, with and without identified risk factors for the coronavirus.

Moderna’s vaccines arrived in Argentina on July 16, thanks to a donation from the United States government. There are 3.5 million doses. They were received on this occasion by the Chief of Staff, Santiago Cafiero, and the Chargé d’affaires of the United States Embassy, ​​MaryKay Carlson.

Source EFE

AFG